AstraZeneca Plunges After Reports of Merger Talks with Bristol Myers Squibb
AstraZeneca shares fell sharply after media reports said the company held preliminary merger discussions with Bristol Myers Squibb that would create a nearly $400 billion combined pharmaceutical group. The news triggered a broad sell-off in AstraZeneca stock and left analysts warning of regulatory and strategic uncertainties that could keep the sha…